| Literature DB >> 29689049 |
Mei Yang1, Junfang Zhang1, Shu Su1, Bai Qin1, Lihua Kang1, Rongrong Zhu1, Huaijin Guan1.
Abstract
PURPOSE: Age-related cataract (ARC) is a leading cause of visual impairment and blindness worldwide. DNA damage and malfunction of DNA repair are believed to contribute to the pathogenesis of ARC. Aside from increasing age, the risk factors for ARC appear to be rather complex, and one or more gene variations could play critical roles in the diverse processes of ARC progression. This study aimed to investigate the combined effects of different genetic variants on ARC risk.Entities:
Mesh:
Year: 2018 PMID: 29689049 PMCID: PMC5915686 DOI: 10.1371/journal.pone.0184478
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Demographic characteristics of the study participants.
| Control (N = 531) | ARC (N = 789) | ||||
|---|---|---|---|---|---|
| Mean± SD | N(%) | Mean± SD | N(%) | ||
| Age(years) | 69.66±4.51 | 70.38±7.72 | 0.053 | ||
| Gender | 0.057 | ||||
| Male | 240(45.2) | 315(39.9) | |||
| Female | 291(54.8) | 474(60.1) | |||
| Fasting blood sugar | 5.19± 0.88 | 5.28± 0.85 | 0.063 | ||
Allele distribution of SNPs in control and ARC subjects.
| Gene name | SNPs Major/minor | Allele distribution Major/minor (%) | P | OR(95%CI) | |
|---|---|---|---|---|---|
| Control | All cases | ||||
| rs1063147 ( | 898/164 (84.6) | 1312/266(83.1) | 0.36 | 1.11(0.90–1.37) | |
| rs7183308 ( | 1010/52(95.1) | 1489/89(94.4) | 0.41 | 1.16(0.82–1.65) | |
| rs17273206 ( | 829/233(78.1) | 1206/372(76.4) | 0.33 | 1.10(0.91–1.32) | |
| rs8027126 ( | 978/84(92.1) | 1445/133(91.6) | 0.63 | 1.07(0.81–1.43) | |
| rs7175811 ( | 766/296(72.1) | 1116/462(70.7) | 0.43 | 1.07(0.90–1.27) | |
| rs3815003 ( | 762/300(71.8) | 1101/477(69.8) | 0.27 | 1.10(0.93–1.31) | |
| rs6496724 ( | 738/324(69.5) | 1059/519(67.1) | 0.20 | 1.12(0.94–1.32) | |
| rs4733220 ( | 620/442(58.4) | 955/623(60.5) | 0.27 | 0.92(0.78–1.07) | |
| rs2725361 ( | 693/369(65.3) | 988/590(62.6) | 0.17 | 1.12(0.95–1.32) | |
| rs2725338 ( | 779/283(73.4) | 1187/391(75.2) | 0.30 | 0.91(0.76–1.08) | |
| rs1801195 ( | 686/376(64.6) | 985/593(62.4) | 0.26 | 1.10(0.93–1.29) | |
| rs2725383 ( | 945/117(89.0) | 1363/215(86.4) | 0.06 | 1.27(1.00–1.62) | |
| rs1863280 ( | 831/231(78.3) | 1229/349(77.9) | 0.82 | 1.02(0.85–1.23) | |
| rs11574311 ( | 950/112(89.5) | 1342/236(85.0) | 0.003 * | 1.49(1.17–1.90) | |
| rs4838519 ( | 539/523(50.8) | 801/777(50.8) | 0.99 | 1.00(0.86–1.17) | |
| rs4253038 ( | 730/332(68.7) | 1057/521(67.0) | 0.35 | 1.08(0.92–1.28) | |
| rs2072668 ( | 636/426(59.9) | 978/600(62.0) | 0.30 | 0.92(0.78–1.07) | |
| rs2304277 ( | 616/446(58.0) | 960/618(60.8) | 0.14 | 0.89(0.76–1.04) | |
Genotype distribution of SNPs in control and ARC subjects.
| Gene | SNPs Major/minor | Genotype distribution (%) | P | Dominant OR(95%CI) | Recessive OR(95%CI) | ||
|---|---|---|---|---|---|---|---|
| Control | ARC | ||||||
| rs1063147 | 379(71.37) | 544(68.95) | 0.624 | 1.12 (0.88–1.43) | 1.18 (0.58–2.42) | ||
| 140(26.37) | 224(28.39) | ||||||
| 12(2.26) | 21(2.66) | ||||||
| rs7183308 | 479(90.21) | 702(88.97) | 0.429 | 1.14 (0.79–1.64) | _ | ||
| 52(9.79) | 85(10.77) | ||||||
| 0(0.00) | 2(0.25) | ||||||
| rs17273206 | 323(60.83) | 463(58.68) | 0.582 | 1.09 (0.87–1.37) | 1.25 (0.76–2.07) | ||
| 183(34.46) | 280(35.49) | ||||||
| 25(4.71) | 46(5.83) | ||||||
| rs7175811 | 277(52.17) | 401(50.82) | 0.640 | 1.06 (0.85–1.32) | 1.21 (0.81–1.79) | ||
| 212(39.92) | 314(39.80) | ||||||
| 42(7.91) | 74(9.38) | ||||||
| rs3815003 | 274(51.60) | 383(48.54) | 0.535 | 1.13 (0.90–1.41) | 1.22 (0.76–1.67) | ||
| 214(40.30) | 335(42.46) | ||||||
| 43(8.10) | 71(9.00) | ||||||
| rs6496724 | 263(49.53) | 361(45.75) | 0.401 | 1.16 (0.93–1.45) | 1.11 (0.78–1.57) | ||
| 212(39.92) | 337(42.71) | ||||||
| 56(10.55) | 91(11.53) | ||||||
| rs4733220 | 190(35.78) | 282(35.74) | 0.088 | 1.00 (0.80–1.26) | 0.73 (0.55–0.98) | ||
| 240(45.20) | 391(49.56) | ||||||
| 101(19.02) | 116(14.70) | ||||||
| rs2725361 | 227(42.75) | 312(39.54) | 0.386 | 1.14 (0.91–1.43) | 1.20 (0.86–1.66) | ||
| 239(45.01) | 364(46.13) | ||||||
| 65(12.24) | 113(14.32) | ||||||
| rs2725338 | 290(54.61) | 448(56.78) | 0.491 | 0.92 (0.73–1.14) | 0.79 (0.51–1.21) | ||
| 199(37.48) | 291(36.88) | ||||||
| 42(7.91) | 50(6.34) | ||||||
| rs1801195 | 227(42.75) | 311(39.42) | 0.479 | 1.15 (0.92–1.44) | 1.09 (0.79–1.49) | ||
| 232(43.69) | 363(46.01) | ||||||
| 72(13.56) | 115(14.58) | ||||||
| rs2725383 | 422(79.47) | 594(75.29) | 0.148 | 1.27 (0.98–1.66) | 1.70 (0.74–3.89) | ||
| 101(19.02) | 175(22.18) | ||||||
| 8(1.51) | 20(2.53) | ||||||
| rs1863280 | 326(61.39) | 474(60.08) | 0.718 | 1.06 (0.84–1.32) | 0.87 (0.52–1.48) | ||
| 179(33.71) | 281(35.61) | ||||||
| 26(4.90) | 34(4.31) | ||||||
| rs11574311 | 428(80.60) | 575(72.88) | 0.005 | 1.55 (1.19–2.01) | 1.66 (0.76–3.64) | ||
| 94(17.70) | 192(24.33) | ||||||
| 9(1.69) | 22(2.79) | ||||||
| rs4838519 | 135(39.36) | 208(60.64) | 0.286 | 0.95 (0.74–1.22) | 1.18 (0.92–1.53) | ||
| 269(42.30) | 367(57.70) | ||||||
| 127(37.24) | 214(62.76) | ||||||
| rs4253038 | 247(46.52) | 359(45.50) | 0.349 | 1.04 (0.84–1.30) | 1.31 (0.91–1.90) | ||
| 236(44.44) | 339(42.97) | ||||||
| 48(9.04) | 91(11.53) | ||||||
| rs2072668 | 195(36.72) | 308(15.08) | 0.560 | 0.91 (0.72–1.14) | 0.87 (0.65–1.17) | ||
| 246(46.33) | 362(45.88) | ||||||
| 90(16.95) | 308(39.04) | ||||||
| rs2304277 | 184(34.65) | 295(37.39) | 0.322 | 0.89 (0.71–1.12) | 0.81 (0.61–1.09) | ||
| 248(46.70) | 370(46.89) | ||||||
| 99(18.64) | 124(15.72) | ||||||
Association of higher-order interactions with overall ARC risk based on MDR Analysis.
| No. of interacting loci | Best Interaction Model | Testing Accuracy | CVC | |
|---|---|---|---|---|
| ALL | ||||
| 1 | 0.5378 | 10/10 | 0.001 | |
| 2 | 0.6193 | 10/10 | <0.001 | |
| 3 | 0.6199 | 6/10 | <0.001 | |
| 4 | 0.6266 | 6/10 | <0.001 | |
| 5 | 0.6273 | 10/10 | <0.001 | |
| C | ||||
| 1 | 0.5637 | 10/10 | <0.001 | |
| 2 | 0.6228 | 9/10 | <0.001 | |
| 3 | 0.6301 | 4/10 | <0.001 | |
| 4 | 0.6397 | 5/10 | <0.001 | |
| N | ||||
| 1 | 0.5333 | 8/10 | 0.038 | |
| 2 | 0.6157 | 10/10 | <0.001 | |
| 3 | 0.6287 | 9/10 | <0.001 | |
| 4 | 0.6042 | 4/10 | <0.001 | |
| 5 | 0.5595 | 7/10 | 0.01 | |
| M | ||||
| 1 | 0.5817 | 7/10 | 0.001 | |
| 2 | 0.6051 | 10/10 | <0.001 | |
| 3 | 0.6319 | 10/10 | <0.001 | |
| 4 | 0.6292 | 6/10 | <0.001 |
Risk estimates of CART Terminal Nodes for all ARC patients.
| Nodes | OR(95%CI) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | - | - | - | Reference | |||||
| 2 | - | - | 0.76 | 1.22(0.34–4.32) | |||||
| 3 | - | 0.45 | 1.63(0.46–5.72) | ||||||
| 4 | 0.14 | 2.36(0.75–7.43) | |||||||
| P trend | <0.001 |
Risk estimates of CART Terminal Nodes for patients with the C subtype of ARC.
| Nodes | OR(95%CI) | ||||
|---|---|---|---|---|---|
| 1 | - | Reference | |||
| 2 | 0.23 | 1.34(0.83–2.16) | |||
| 3 | <0.001 | 2.38(1.41–4.02) | |||
| 4 | <0.001 | 6.31(2.59–15.38) | |||
| P trend | <0.001 |
Risk estimates of CART Terminal Nodes for patients with the N subtype of ARC.
| Nodes | OR(95%CI) | ||||||
|---|---|---|---|---|---|---|---|
| 1 | - | Reference | |||||
| 2 | 0.64 | 1.19(0.59–2.40) | |||||
| 3 | 0.26 | 1.41(0.78–2.54) | |||||
| 4 | 0.07 | 1.55(0.97–2.48) | |||||
| 5 | <0.001 | 2.81(1.54–5.10) | |||||
| 6 | <0.001 | 4.88(1.97–12.06) | |||||
| P trend | <0.001 |
Risk estimates of CART Terminal Nodes for patients with the M subtype of ARC.
| Nodes | OR(95%CI) | |||||
|---|---|---|---|---|---|---|
| 1 | - | Reference | ||||
| 2 | 0.52 | 1.34(0.55–3.26) | ||||
| 3 | 0.28 | 1.94(0.58–6.47) | ||||
| 4 | 0.001 | 5.00(1.82–13.70) | ||||
| 5 | <0.001 | 8.57(2.32–31.72) | ||||
| P trend | <0.001 |
Mean GRSs according to ARC subtype and corresponding P-values.
| Control | Case | |||
|---|---|---|---|---|
| All ARC | 11.46±3.77 | 12.08±4.07 | -2.80 | 0.005 |
| C | 11.46±3.77 | 12.14±4.01 | -2.33 | 0.019 |
| N | 11.46±3.77 | 12.00±4.18 | -2.03 | 0.042 |
| M | 11.46±3.77 | 12.17±3.81 | -1.93 | 0.054 |